NEOSALUS CREAM Rx
Generic Name and Formulations:
Carbomer, dimethicone, ethylparaben, glycerin, methylparaben, phenoxyethanol, polysorbate 20, povidone, propylene glycol, propylparaben, purified water, sodium hydroxide, stearic acid, trolamine; fragrance-free.
Indications for NEOSALUS CREAM:
Dermatitis (eg, atopic dermatitis, contact dermatitis).
Adults and Children:
Apply to affected areas 3 times daily or as needed.
Avoid contact with eyes, lips, angles of the nose, and mucous membranes. Discontinue if sensitivity or irritation occurs. Avoid exposure to sun or UV light.
Erythema, dryness, scaling, burning, pruritus.
Foam—10g, 70g, 200g; Crm—60g, 100g; Lotion—236mL
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments